Study of Autologous Tumor Lysate-pulsed D-CIK Combined With Chemotherapy for Gastric Cancer

• Status: Unknown status
• Trial end date: 2018-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and efficacy of chemotherapy combined with autologous tumor Lysate-pulsed dendritic with cytokine-induced killer cell (Ag-D-CIK) for gastric cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shenzhen Hornetcorn Bio-technology Company, LTD
• Collaborators: Affiliated Cancer Hospital & Institute of Guangzhou Medical University; Affiliated Tumor Hospital of Guangzhou Medical University; Jingzhou Central Hospital

Criteria

Inclusion Criteria:

• Patients who can accept curative operations

• 18~80 years old

• Histologically confirmed with gastric cancer at stage Ⅰ~Ⅲ

• Patients who can accept radical gastrectomy;

• Eastern Cooperative Oncology Group (ECOG) performance status was 0 - 1.

Exclusion Criteria:

• Hemoglobin<8.0 g/dL,White blood cell <3 x 10^9/L;Platelet count <75 x 10^9/L; ALT, AST, BUN and Cr more than normal limits on 3.0 times

• Known or suspected allergy to the investigational agent or any agent given in association with this trial

• Pregnant or lactating patients

• Known history of Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV) or TreponemaPallidun (TP) infection

• Patients who are suffering from serious autoimmune disease

• Patients who had used long time or are using immunosuppressant

• Patients who had active infection

• Patients who are suffering from serious organ dysfunction

• Patients who are suffering from other cancer

• Other situations that the researchers considered unsuitable for this study.